Analyst Reco. United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 20:00:00 12/03/2026 GMT			5-day change	1st Jan Change
532.82 ^USD	-2.18%		+9.85%	+9.35%

03-11	United Therapeutics Corporation Publishes Full Results Of TETON-2 Phase 3 Clinical Trial For Tyvaso Inhalation Solution	CI
03-09	BETA Technologies Participates In FAA?s eVTOL Integration Pilot Program Across 10 States	CI

Analyst Reco.

03-05	United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says	MT
03-05	UBS Adjusts Price Target on United Therapeutics to $705 From $655, Maintains Buy Rating	MT
02-26	United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says	MT
02-26	Oppenheimer Adjusts United Therapeutics Price Target to $600 From $575, Maintains Outperform Rating	MT
02-26	RBC Raises Price Target on United Therapeutics to $643 From $587, Keeps Outperform Rating	MT
01-06	UBS Adjusts Price Target on United Therapeutics to $645 From $600, Maintains Buy Rating	MT
11-06	UBS Adjusts Price Target on United Therapeutics to $600 From $580, Maintains Buy Rating	MT
31/10/25	Analyst recommendations: Comcast, Roblox, Alphabet, Reddit, Western Digital…
09/10/25	BofA Cuts Price Target on United Therapeutics to $461 From $463	MT
29/09/25	UBS Adjusts United Therapeutics Price Target to $580 From $560, Maintains Buy Rating	MT
26/09/25	United Therapeutics' Tyvaso Success in IPF to Unlock Big Market Opportunity, RBC Says	MT
26/09/25	RBC Initiates United Therapeutics at Outperform With $569 Price Target	MT
10/09/25	Analyst recommendations: Apple, Oracle, Synopsys, Robinhood Markets, American Electric Power...
05/09/25	United Therapeutics' Tyvaso Win in IPF Clears Path for More Revenue, Oppenheimer Says	MT
05/09/25	Oppenheimer Adjusts Price Target on United Therapeutics to $575 From $510, Maintains Outperform Rating	MT
04/09/25	UBS Adjusts Price Target on United Therapeutics to $560 From $415, Maintains Buy Rating	MT
03/09/25	Analyst recommendations: Accenture, Chipotle, Kraft, Lucid Group, Thor Industries…
02/09/25	TD Cowen Adjusts Price Target on United Therapeutics to $500 From $400, Maintains Buy Rating	MT
13/08/25	UBS Adjusts United Therapeutics Price Target to $415 From $385, Maintains Buy Rating	MT
14/07/25	United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says	MT
30/06/25	UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	MT
02/06/25	Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target	MT
21/04/25	BofA Securities Upgrades United Therapeutics to Neutral From Underperform	MT
18/03/25	UBS Adjusts Price Target on United Therapeutics to $410 From $440, Maintains Buy Rating	MT
06/02/25	UBS Adjusts Price Target on United Therapeutics to $460 From $475, Keeps Buy Rating	MT